论文部分内容阅读
[目的]评价替吉奥胶囊联合奥沙利铂治疗贲门癌患者的临床疗效。[方法]60例贲门癌患者,分成观察组和对照组。对照组采用卡培他滨联合奥沙利铂治疗;观察组采用替吉奥胶囊联合奥沙利铂治疗。[结果]观察组临床疗效、KPS评分情况与对照组相比,差异无统计学意义(P﹥0.05)。对照组不良反应多于观察组,差异有统计学意义(P﹤0.05)。[结论替吉奥胶囊联合奥沙利铂治疗贲门癌患者疗效佳,且有较高的安全性。
[Objective] To evaluate the clinical efficacy of tigeo capsule combined with oxaliplatin in the treatment of cardia cancer patients. [Method] Sixty patients with cardiac cancer were divided into observation group and control group. The control group was treated with capecitabine combined with oxaliplatin; the observation group was treated with tigegio capsule combined with oxaliplatin. [Result] The clinical curative effect and KPS score in the observation group were not significantly different from those in the control group (P> 0.05). Adverse reactions in the control group were more than those in the observation group, with significant differences (P <0.05). [Conclusion] TIGO capsules combined with oxaliplatin in the treatment of patients with cardia cancer have good curative effect and high safety.